Why it Matters

A package of healthcare bills heading to a Senate Committee on Health, Education, Labor, and Pensions (HELP) meeting on Wednesday, June 17 touches nearly every corner of federal health policy — from disability rights in organ transplants to ALS research funding, drug patent reform, and maternal health. Several of the authorizations on the table expire this year, meaning inaction could wind down programs that patients and advocates depend on.

Sen. Bill Cassidy (R-LA) will be charing the meeting, and Sen. Bernie Sanders (I-VT) will serve as Ranking Member.

The Big Picture

The most politically charged bill on the docket may be S.1782, the Charlotte Woodward Organ Transplant Discrimination Prevention Act, which would ban discrimination on the basis of mental or physical disability in organ transplant decisions. The bill, named for disability rights advocate Charlotte Woodward — a woman with Down syndrome who has spoken publicly about being denied transplants due to her disability — has been introduced to Congress previously and cleared the House in May 2025. Despite 18 cosponsors, including HELP Committee members Sen. Margaret Hassan (D-NH) and Sen. Tim Kaine (D-VA), the bill hit Senate roadblocks as recently as April 2026, with Chair Cassidy citing stakeholder concerns. The National Down Syndrome Society and the National Down Syndrome Congress have both lobbied in connection with the bill.

Three programs face expiration this year, giving the business meeting added urgency:

  • S.4109, or Stem Cell Therapeutic and Research Act of 2005, expires in 2026. The bill would extend the C.W. Bill Young Cell Transplantation Program, raising annual funding from $31 million to $33 million for fiscal years 2027–2031, and push the national cord blood inventory program's authorization deadline from 2026 to 2031.
  • S.4472, sponsored by HELP Committee member Sen. Lisa Murkowski (R-AK), would extend the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. The original law, enacted in December 2021, authorized $100 million per year for FY2022–2026. The ALS Network has publicly called on Congress to act swiftly, warning that without reauthorization, ALS research programs would begin to wind down.
  • S.2339 would extend the Young Women's Breast Health Education and Awareness Requires Learning Young (EARLY) Act from 2026 to 2031. Its House companion, H.R.4541, cleared the Committee on Energy and Commerce in a voice vote May 21.

The committee will also take up S.2658, the Medication Affordability and Patent Integrity Act, introduced by HELP Committee members Hassan and Sen. Josh Hawley (R-MO). The bill would require drug sponsors to submit consistent patent information to both the FDA and the Patent and Trademark Office, targeting a practice where manufacturers allegedly make conflicting patent claims to different federal agencies to extend exclusivity and delay generic competition. GSK plc, the Pharmaceutical Research and Manufacturers of America (PhRMA), and Fresenius Kabi USA LLC have all lobbied in connection with the bill.

Rounding out the healthcare legislation package, S.3014 would amend the Federal Food, Drug, and Cosmetic Act on citizen petitions, a process that has been documented as a tactic used by brand-name manufacturers to delay generic drug approvals. S.1954 would tighten the requirements for determining interchangeability between a biological product and its reference product, and S.3799 would reauthorize the Healthy Start Initiative at $145 million annually through fiscal year 2030.